Diabetes drug semaglutide put to the test: can it reveal secrets of the adrenal gland?

NCT ID NCT06608433

Completed Knowledge-focused Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study gave 22 healthy men a single dose of semaglutide (Rybelsus) or a placebo pill to see how it affects cortisol and other stress hormones. The goal was not to treat any disease, but to learn more about how GLP-1 drugs interact with the body's stress system. Participants were healthy males aged 18-60 with no regular medications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide (Rybelsus)
What this could lead to: If successful, this could help researchers understand how GLP-1 drugs like semaglutide affect stress hormones and adrenal function.
What could go wrong: This is a very small, early-stage study in healthy volunteers, not patients. It only looks at hormone changes after a single dose, so results may not apply to long-term use or people with adrenal conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADRENAL INSUFFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adrenocortical insufficiency heritable pulmonary arterial hypertension mild hyperphenylalaninemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADRENAL INSUFFICIENCY CORTISOL DEFICIENCY HEALTHY VOLUNTEER STUDY HPA

Contacts and locations

Locations

University Hospital Basel

Basel, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.